Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 21Brain Neoplasms 9Neoplasms 7Glioma 6Astrocytoma 4Recurrence 3Solid Tumor 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

motexafin gadolinium 1Talaporfin 1Rhenium 1Poly I-C 1Mitomycin 1Lomustine 1Folfox protocol 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasm Recurrence, Local × Lomustine × Clear all
NCT07100730 2026-04-16

IPAX BrIGHT

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡